NCT06897527View on ClinicalTrials.gov

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

January 13, 2027

Study Completion Date

January 13, 2027

Conditions

Neoplasms, Endometrial

Interventions

DRUG

Dostarlimab

Dostarlimab will be administered.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT06897527 - A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC) | Biotech Hunter | Biotech Hunter